AccessibilityHelp

Most Active Stocks Daily Stock Gainers Daily Stock Losers

Most Active Stocks Daily Stock Gainers Daily Stock Losers

Todd Campbell

XMFEBCapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Articles by Todd Campbell — Page 174

What You Should Know About Gilead's Sovaldi And Johnson & Johnson's Olysio

Apr 24, 2014 by Todd Campbell

What You Should Know About Gilead's Sovaldi And Johnson & Johnson's Olysio

Johnson & Johnson's (JNJ) Olysio and Gilead's (GILD) Sovaldi posted blockbuster run rates in the first quarter, but sales could soon be challenged by AbbVie (ABBV), Bristol-Myers (BMY), and Merck (MRK).

Earnings Roundup: Aetna, Inc. Continues the Medicaid Winning Steak

Apr 24, 2014 by Todd Campbell

Earnings Roundup: Aetna, Inc. Continues the Medicaid Winning Steak

Aetna (AET) joined United Healthcare (UNH) and Centene (CNC) in reporting robust first quarter sales and profit growth tied to rising Medicaid enrollment.

3 Drugs Johnson & Johnson’s Investors Better Know About

Apr 24, 2014 by Todd Campbell

3 Drugs Johnson & Johnson’s Investors Better Know About

Johnson & Johnson's (JNJ) sales are being driven by a handful of fast-growing drugs. Here are three investors should be watching because of competitive threats from AstraZeneca (AZN), Pfizer (PFE), and Medivation (MDVN).

Earnings Roundup: Does Medidata's Stumble Present An Opportunity?

Apr 24, 2014 by Todd Campbell

Earnings Roundup: Does Medidata's Stumble Present An Opportunity?

Medidata's (MDSO) first quarter results left investors unimpressed, but a growing industry suggests that Medidata and competitors Oracle (ORCL) Health and IMS (IMS) still have room to expand.

Earnings Roundup: Biogen's Tecfidera Wins More Share

Apr 24, 2014 by Todd Campbell

Earnings Roundup: Biogen's Tecfidera Wins More Share

Biogen's (BIIB) dominance in multiple sclerosis drove sales 50% higher in the first quarter, as Tecfidera successfully expanded market share.

Earnings Roundup: What You Need to Know About Gilead's Blockbuster Quarter

Apr 23, 2014 by Todd Campbell

Earnings Roundup: What You Need to Know About Gilead's Blockbuster Quarter

Gilead (GILD) posted blockbuster sales for Sovaldi, outpacing Johnson & Johnson's (JNJ) Olysio.

Earnings Roundup: athenahealth's Disappointing Quarter

Apr 22, 2014 by Todd Campbell

Earnings Roundup: athenahealth's Disappointing Quarter

The market for healthcare IT has never been stronger, but that did little to calm athenahealth's (ATHN) investors' worry over uninspiring earnings.

Earnings Roundup: Centene's Medicaid Miracle

Apr 22, 2014 by Todd Campbell

Earnings Roundup: Centene's Medicaid Miracle

Centene (CNC) joined United Healthcare (UNH) in reporting impressive Medicaid revenue, setting the stage for Molina (MOH) to beat when it reports on May 1st.

Earnings Roundup: Baxter International Grows Ahead of Its Spin-Off

Apr 22, 2014 by Todd Campbell

Earnings Roundup: Baxter International Grows Ahead of Its Spin-Off

Sales at Baxter (BAX) biopharma and medical device businesses headed higher in the first quarter, suggesting a bright future for Baxter's planned separation of its biopharma and medical device business next year.

Allergan: Here's Why Ackman and Valeant Want the Botox Maker

Apr 22, 2014 by Todd Campbell

Allergan: Here's Why Ackman and Valeant Want the Botox Maker

Here's what you need to know about Valeant's (VRX) planned $45 billion acquisition of Allergan (AGN),

Warfarin's Loss is Johnson & Johnson's Gain

Apr 21, 2014 by Todd Campbell

Warfarin's Loss is Johnson & Johnson's Gain

Factor Xa-inhibiting anticoagulants like Johnson & Johnson's Xarelto are rapidly winning prescriptions away from warfarin and Boehringer's Pradaxa.

Johnson & Johnson's New Diabetes Drug: A Blockbuster in the Making?

Apr 21, 2014 by Todd Campbell

Johnson & Johnson's New Diabetes Drug: A Blockbuster in the Making?

Johnson's Invokana is about to face a host of new SGLT2 competitors from AstraZeneca, Merck, and Eli Lilly.

Earnings Roundup: Look Beyond Abbott Labs' Short-term Bumps

Apr 20, 2014 by Todd Campbell

Earnings Roundup: Look Beyond Abbott Labs' Short-term Bumps

A recall in Abbott Labs (ABT) nutrition segment gave Mead Johnson (MJN) an edge, but that and other short-term hurdles shouldn't distract investors from the company's long-term opportunity.

How Big Is the Threat to This Johnson & Johnson Blockbuster?

Apr 18, 2014 by Todd Campbell

How Big Is the Threat to This Johnson & Johnson Blockbuster?

Growth for Johnson & Johnson's (JNJ) blockbuster Zytiga is being weighed down by Medivation (MDVN) and Astellas (ALPMY) Xtandi.

Earnings Roundup: Johnson & Johnson Results Are Better Than They Appear

Apr 17, 2014 by Todd Campbell

Earnings Roundup: Johnson & Johnson Results Are Better Than They Appear

Slow growth from medical device and consumer goods masked robust sales in Johnson & Johnson's drug business.

Earnings Roundup: Did Obamacare Swamp United Healthcare's Quarter?

Apr 17, 2014 by Todd Campbell

Earnings Roundup: Did Obamacare Swamp United Healthcare's Quarter?

Medicaid membership surged at United Healthcare (UNH) in Q1, offsetting headwinds tied to Obamacare fees and higher taxes, and suggesting strong results for Medicaid insurers Molina (MOH) and Centene (CNC).

3 Reasons Rite Aid Continues to Crush the Market

Apr 17, 2014 by Todd Campbell

3 Reasons Rite Aid Continues to Crush the Market

Shares in Rite Aid (RAD) may keep heading higher thanks to these three reasons.

Earnings Roundup: St. Jude's 1 Bright Spot

Apr 17, 2014 by Todd Campbell

Earnings Roundup: St. Jude's 1 Bright Spot

St Jude's (STJ) electrophysiology business is the one bright spot in an otherwise dim earnings report.

Earnings Primer: What's on Deck for Celgene, AbbVie, and Gilead

Apr 17, 2014 by Todd Campbell

Earnings Primer: What's on Deck for Celgene, AbbVie, and Gilead

Here's what you need to know about Celgene (CELG), AbbVie (ABBV), and Gilead (GILD) before they report their first quarter earnings later this month.

Earnings Primer: What's on Deck for Amgen Inc. and Biogen Idec Inc.

Apr 17, 2014 by Todd Campbell

Earnings Primer: What's on Deck for Amgen Inc. and Biogen Idec Inc.

Here's what you need to know about Amgen (AMGN) and Biogen's (BIIB) upcoming first quarter earnings report.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services